ENLV PE Ratio & Valuation,Is ENLV Overvalued

ENLV Relative Valuation

ENLV's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ENLV is overvalued; if below, it's undervalued.

Historical Valuation

Enlivex Therapeutics Ltd (ENLV) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -4.07. The fair price of Enlivex Therapeutics Ltd (ENLV) is between -- to -- according to relative valuation methord.

Relative Value

Fair Zone

-----

Current Price：0.87

Fair

-1.66

0.00

EV/EBITDA

Enlivex Therapeutics Ltd. (ENLV) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

-0.26

EV/EBIT

Enlivex Therapeutics Ltd. (ENLV) has a current EV/EBIT of -0.26. The 5-year average EV/EBIT is -1.77. The thresholds are as follows: Strongly Undervalued below -7.71, Undervalued between -7.71 and -4.74, Fairly Valued between 1.21 and -4.74, Overvalued between 1.21 and 4.18, and Strongly Overvalued above 4.18. The current Forward EV/EBIT of -0.26 falls within the Historic Trend Line -Fairly Valued range.

0.00

Enlivex Therapeutics Ltd. (ENLV) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.

-0.95

P/OCF

Enlivex Therapeutics Ltd. (ENLV) has a current P/OCF of -0.95. The 5-year average P/OCF is -0.82. The thresholds are as follows: Strongly Undervalued below -3.29, Undervalued between -3.29 and -2.06, Fairly Valued between 0.41 and -2.06, Overvalued between 0.41 and 1.65, and Strongly Overvalued above 1.65. The current Forward P/OCF of -0.95 falls within the Historic Trend Line -Fairly Valued range.

-0.95

P/FCF

Enlivex Therapeutics Ltd. (ENLV) has a current P/FCF of -0.95. The 5-year average P/FCF is -0.88. The thresholds are as follows: Strongly Undervalued below -3.60, Undervalued between -3.60 and -2.24, Fairly Valued between 0.49 and -2.24, Overvalued between 0.49 and 1.85, and Strongly Overvalued above 1.85. The current Forward P/FCF of -0.95 falls within the Historic Trend Line -Fairly Valued range.

Enlivex Therapeutics Ltd (ENLV) has a current Price-to-Book (P/B) ratio of 1.29. Compared to its 3-year average P/B ratio of 1.19 , the current P/B ratio is approximately 8.67% higher. Relative to its 5-year average P/B ratio of 1.55, the current P/B ratio is about -16.79% higher. Enlivex Therapeutics Ltd (ENLV) has a Forward Free Cash Flow (FCF) yield of approximately -53.04%. Compared to its 3-year average FCF yield of -58.56%, the current FCF yield is approximately -9.43% lower. Relative to its 5-year average FCF yield of -42.30% , the current FCF yield is about 25.39% lower.

1.20

P/B

Median3y

1.19

Median5y

1.55

-53.04

FCF Yield

Median3y

-58.56

Median5y

-42.30

Competitors Valuation Multiple

The average P/S ratio for ENLV's competitors is 0.00, providing a benchmark for relative valuation. Enlivex Therapeutics Ltd Corp (ENLV) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of ENLV increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of ENLV in the past 1 year is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is Enlivex Therapeutics Ltd (ENLV) currently overvalued or undervalued?

What is Enlivex Therapeutics Ltd (ENLV) fair value?

ENLV's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Enlivex Therapeutics Ltd (ENLV) is between to according to relative valuation methord.

How does ENLV's valuation metrics compare to the industry average?

What is the current P/B ratio for Enlivex Therapeutics Ltd (ENLV) as of Dec 16 2025?

As of Dec 16 2025, Enlivex Therapeutics Ltd (ENLV) has a P/B ratio of 1.29. This indicates that the market values ENLV at 1.29 times its book value.

What is the current FCF Yield for Enlivex Therapeutics Ltd (ENLV) as of Dec 16 2025?

As of Dec 16 2025, Enlivex Therapeutics Ltd (ENLV) has a FCF Yield of -53.04%. This means that for every dollar of Enlivex Therapeutics Ltd’s market capitalization, the company generates -53.04 cents in free cash flow.

What is the current Forward P/E ratio for Enlivex Therapeutics Ltd (ENLV) as of Dec 16 2025?

As of Dec 16 2025, Enlivex Therapeutics Ltd (ENLV) has a Forward P/E ratio of -1.79. This means the market is willing to pay $-1.79 for every dollar of Enlivex Therapeutics Ltd’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Enlivex Therapeutics Ltd (ENLV) as of Dec 16 2025?

As of Dec 16 2025, Enlivex Therapeutics Ltd (ENLV) has a Forward P/S ratio of 0.00. This means the market is valuing ENLV at $0.00 for every dollar of expected revenue over the next 12 months.

ENLV Valuation